Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
3.390
-0.140 (-3.97%)
At close: May 13, 2025, 4:00 PM
3.390
0.00 (0.00%)
Pre-market: May 14, 2025, 4:50 AM EDT
Ardelyx Employees
Ardelyx had 395 employees as of December 31, 2024. The number of employees increased by 128 or 47.94% compared to the previous year.
Employees
395
Change (1Y)
128
Growth (1Y)
47.94%
Revenue / Employee
$915,711
Profits / Employee
-$136,106
Market Cap
811.08M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ARDX News
- 7 days ago - Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference - GlobeNewsWire
- 11 days ago - Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty - Seeking Alpha
- 12 days ago - Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 14 days ago - Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors - GlobeNewsWire
- 19 days ago - Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference - GlobeNewsWire
- 26 days ago - Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025 - GlobeNewsWire
- 4 weeks ago - Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings - GlobeNewsWire